Your 10-Step Action Plan for the 2026 QMSR Transition
The FDA's new Quality Management System Regulation is live. Most manufacturers are not ready. This guide shows you exactly what to do next.
1
Business Day Notice from FDA
20+
Years of OEM Experience
10
Actionable Steps Inside
No credit card required. Instant access upon form submission.
The Challenge
The Biggest Regulatory Shift in 20 Years — and Most Manufacturers Are Behind
QMSR doesn’t introduce entirely new problems. It intensifies the ones you already have. Manual systems that were barely keeping up with the old QSR are now facing a standard of rigor they cannot sustain.
The Rollsuphill Effect
A single unresolved CAPA can escalate into a Form 483, then a Warning Letter, then a Consent Decree. Under QMSR, the triggers are more numerous and the speed of escalation is faster. Small problems don’t stay small.
The QMSR Scalability Crisis
Traditional, manual quality systems cannot sustain the documentation rigor, supplier oversight, and risk management requirements of the new regulation. Audit preparation alone can consume 200–400 hours of staff time.
The 1-Day Notice Reality
The FDA published its new inspection manual (CPM 7382.845A) just one business day before QMSR went live. If you haven’t been preparing for years, you are already behind the standard the FDA expects.
The Rollsuphill Effect
How a Small Problem Becomes a Catastrophe
Quality problems do not stay contained. They roll uphill, gathering mass and momentum. Here is the escalation path that every manufacturer must understand — and prevent.
Unresolved CAPA
A minor non-conformance is identified in an internal audit. The CAPA is opened but never properly closed. It seems insignificant — a low-priority item in a long queue.
Cost: Staff time + internal disruptionFDA Form 483 Observation
An FDA investigator discovers the open CAPA during a routine inspection. You now have a formal observation requiring a written response and a resource-intensive corrective action plan.
Cost: Tens of thousands in remediationFDA Warning Letter
Your response to the 483 is deemed inadequate. A public Warning Letter is issued, triggering mandatory remediation programs that consume years of management attention and millions of dollars.
Cost: Millions in remediation + reputational damageConsent Decree
Failure to adequately address the Warning Letter leads to a Consent Decree — a legal agreement that can effectively shut down your ability to ship product and result in catastrophic, potentially irreversible revenue loss.
Cost: Catastrophic — potential business shutdown
What You’ll Receive
A Practical, Step-by-Step Roadmap — Not Another Regulatory Summary
This guide is written by former OEM executives who have lived through FDA inspections, Warning Letters, and quality system overhauls. It gives you the actionable steps you need to move from understanding the changes to implementing them.
MB&A Free Resource
The Ultimate Guide to the 2026 QMSR Transition
- Conduct a Comprehensive Gap Analysis
- Revise Your Quality Manual
- Overhaul Your Supplier Management Program
- Integrate Risk Management Lifecycle-Wide
- Update Your Design Control Procedures
- Strengthen Your CAPA Process
- Enhance Your Management Review Process
- Update Your Internal Audit Program
- Train Your Team on New Requirements
- Prepare for Your First QMSR Inspection
10 Actionable Steps
Each step includes specific, concrete actions you can assign to your team and track to completion.
QSR vs. QMSR Comparison
A clear, side-by-side breakdown of what has changed and what the practical impact is for your quality system.
Financial Impact Analysis
Understand the true cost of non-compliance at every stage of the escalation path, from Form 483 to Consent Decree.
FDA Inspection Readiness
Specific guidance on CPM 7382.845A — the new inspection manual — so you know exactly what an investigator will look for.
The Role of Audit Intelligence
Learn how AI-powered tools can reduce audit preparation time by up to 50% and help you scale your QMS for QMSR demands.
Get Instant Access
Download Your Free QMSR Transition Guide
Complete the form to receive your guide instantly. No spam, no sales calls unless you request them — just the information you need to protect your business.
Your information is 100% secure and will never be shared.
Instant delivery — the guide is sent immediately to your inbox.
Written specifically for OEMs and Contract Manufacturers.
Created by former OEM executives with 20+ years of FDA experience.
Get the Free Guide
Fill in your details below for instant access.
By submitting this form, you agree to receive the requested resource and occasional relevant communications from MB&A. You may unsubscribe at any time. We respect your privacy.
About MB&A
We Know What Great Looks Like.
MB&A — Monica Burt & Burt and Associates is a team of seasoned MedTech professionals with decades of experience in corporate OEM quality and regulatory affairs. We are not generalist consultants; we are former industry insiders who have built, managed, and defended quality systems at the companies your team works with every day.
Former OEM executives with hands-on FDA inspection experience
Deep expertise in orthopedic, spine, and cardiovascular device manufacturing
Specialists in regulatory affairs, quality compliance, and supplier oversight
Trusted by mid-size and large OEMs across the U.S. medical device industry
Don’t Wait for a Form 483 to Find Out You’re Not Ready.
Download the free guide and take the first step toward a seamless, confident QMSR transition.
Download the Free Guide Now →